News

In a large study, an examination of patterns of use.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help HIV patients.

Uncovering interesting findings regarding patients' PrEP regimen.

How much does the current virus crisis share in common with early HIV outbreak scare?

Time interval goes down by 3 months in 3 year period.

Investigators compared characteristics and retention between daily and event-driven PrEP patients to better understand low uptake of event-driven PrEP.

Experts assessed the impact of drug overdoses on people living with HIV in British Columbia, identifying factors associated with mortality using competing risk methodology.

People with HIV are living longer than ever at present time, raising quality of life concerns about later stage medical and psychological challenges comorbidities.

Small study shows HIV patients not at a greater risk for worse outcomes.

The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.

With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.

With insufficient HIV diagnosis testing in that country, this novel testing could help it reach part of its UNAIDS 90-90-90 targets.

A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.

A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.

In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.

Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.

Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.

Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.

A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.

Despite being within the age group at highest risk for severe SARS-CoV-2 infection, a recent survey suggests that the population is not inherently more willing to socially isolate.

Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.

A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.

CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.

How the inflammatory-based syndrome is affecting US children during the COVID-19 pandemic.

A discussion on how the pediatric inflammatory syndrome has begun to affect the US months into the pandemic.

Black Americans bear a disproportional burden and negative outcomes from the coronavirus.

Catch up with a review of our top drug pipeline stories from the past week.

. The following is a list of key recalls that may be relevant to infectious diseases, with links to full recall statements.

Hospitalized patients with unverified penicillin allergies may unnecessarily face greater risk of adverse drug events when given broader spectrum alternative antibiotics, according to a new study.